Design of a ProDer f 1 vaccine delivered by the MHC class II pathway of antigen presentation and analysis of the effectiveness for specific immunotherapy.

Zhiming Liu, Yuxin Jiang, Chaopin Li

Open access · greenAbstract read

In one paragraph

Article in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

0.2field-weighted citation impact, top 43% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Zhiming LiuDepartment of Medical Parasitology, Wannan Medical University Wuhu 241002, Anhui, China ; Department of Clinical Laboratory, Affiliated Nanjing Jiangbei Hospital, Medical College of Southeast University Nanjing 210048, China.

Yuxin JiangDepartment of Medical Parasitology, Wannan Medical University Wuhu 241002, Anhui, China.

Chaopin LiDepartment of Medical Parasitology, Wannan Medical University Wuhu 241002, Anhui, China.

Wannan Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dermatophagoides farinae (Der f 1) is one of leading cause for allergic asthma, and allergen-specific immunotherapy (SIT) is currently recognized as the only etiological therapy to ameliorate asthmatic symptom. The current study was designed on the major histocompatibility complex (MHC) class II pathway, invariant chain (Ii)-segment hybrids as vaccine basis to explore the efficacy of Der f 1 hybrid vaccine by virtue of Ii as carrier in enhancing the protective immune response to asthma. Initially, we engineered a fused molecule, DCP-IhC-ProDer f 1, to deliver ProDer f 1 antigen via specific dendritic cell-targeting peptides to dendritic cells (DCs). Then the DCP-IhC-ProDer f 1 was immunized to the asthmatic models of murine induced by ProDer f 1 allergen. The findings showed that the cytokine repertoire in the murine model was shifted after SIT, including stronger secretion of IFN-γ and IL-10, and a decreased production of IL-4 and IL-17. ELISA determination revealed that the hybrid displayed weak IgE and IgG1 reactivities, and IgG2a levels were elevated. Furthermore, DCP-IhC-ProDer f 1 treatment inhibited inflammatory cell infiltration in the lung tissues. Our results suggest that the DCP-Ihc-ProDer f 1 may be used as a candidate SIT against asthma.

Indexed as

AnimalsAntigen PresentationAntigens, DermatophagoidesAntigens, Differentiation, B-LymphocyteArthropod ProteinsAsthmaBlotting, WesternCysteine EndopeptidasesDesensitization, ImmunologicDisease Models, AnimalFemaleHistocompatibility Antigens Class IIMiceMice, Inbred BALB CPolymerase Chain ReactionRecombinant ProteinsAntigens, DermatophagoidesAntigens, Differentiation, B-LymphocyteArthropod ProteinsCysteine EndopeptidasesDermatophagoides farinae antigen f 1Histocompatibility Antigens Class IIinvariant chainRecombinant ProteinsVaccinesdendritic cellDermatophagoides farinaeinvariant chainmajor histocompatibility complexspecific immunotherapy

Identifiers

PMID25197336

PMCPMC4152026

OpenAlexW2265271168

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.